What’s new in the 2021 ESC/EACTS VHD Guidelines?

Referral and treatment recommendations change for sAS patients

With the updated 2021 ESC/EACTS Guidelines for the management of valvular heart disease (VHD), the referral and treatment decisions for patients with severe aortic stenosis (sAS) have changed:1

  • All severe aortic stenosis (sAS) patients* should now be evaluated by the Heart Team1
  • The guidelines recommend TF-TAVI for as the preferred mode of intervention in patients ≥75 years of age**, as well as for additional patient groups <75 years of age1
  • The Heart Team recommendation should be discussed with the patient, who can then make an informed treatment decision between the option of TAVI or SAVR1

*With treatment indication.
**Based on evaluation of clinical, anatomical and procedural factors.

2021 ESC/EACTS VHD Guidelines: Treatment Recommendations for sAS patients

Full guidelines details can be found on the official ESC website, you can also preorder a free pocket guidelines below.

The future of TAVI - Edwards Lifesciences satellite symposium

Listen to leading experts discuss the impact of the updated 2021 ESC/EACTS VHD Guidelines on ESC Congress – The Digital Experience 2021

The Future of TAVI, ESC 2021 - 44 min

  • Introduction, purpose and learning objectives by Professor Bernard Prendergast (00:38)
  • An overview of the 2021 ESC/EACTS Guideline recommendations for the treatment of severe AS and the evidence supporting these changes by Professor Jan-Malte Sinning (04:40)
  • The evolution of the ESC/EACTS Guidelines, the increased number of TAVI procedures, the economic impact of TAVI, and the future role of TAVI in severe AS by Dr. Francesco Saia (12:25)
  • A panel discussion of the topics covered initiated by Professor Martine Gilard (22:53)
  • A case study and discussion on the benefits of holistic management by Professor Jörg Kempfert (31:22)

Free ESC/EACTS Pocket Guidelines for VHD

Sign up to receive:

  • 2021 ESC/EACTS Pocket Guidelines for the management of valvular heart disease
  • Educational emails on Aortic Stenosis Management
  • Useful resources for you and your patients

References:

1. Vahanian A, et al. Eur Heart J. 2021; ehab395. doi:10.1093/eurheartj/ehab395.

Medical device for professional use. For a listing of indications, contraindications, precautions, warnings, and potential adverse events, please refer to the Instructions for Use (consult eifu.edwards.com where applicable).

PP--EU-2675 v4.0